The global corneal ulcer treatment market is projected to grow at a steady compound annual growth rate (CAGR) of 5.7% from 2022 to 2029, according to Future Market Insights. The market, valued at approximately USD 867.3 million in 2022, is expected to experience robust expansion driven by advancements in treatment options and increasing awareness about corneal health.
Antibiotics remain the cornerstone of corneal ulcer management, holding a dominant share of around 76.4% in 2021. These treatments are critical in combating bacterial infections that contribute significantly to corneal ulcers. Rising incidences of eye-related conditions, fueled by factors such as aging populations, increasing screen time, and delayed treatment of eye injuries, are driving demand for effective therapeutic solutions.
The market is further bolstered by innovations in drug delivery systems, such as topical formulations and advanced antibiotic therapies, aimed at improving treatment efficacy and patient outcomes. Emerging economies are also witnessing greater adoption of corneal ulcer treatments as healthcare access improves and ophthalmic care gains priority.
As the market evolves, industry players are focusing on research and development to expand their product portfolios and address unmet needs. The corneal ulcer treatment market is poised to play a pivotal role in preserving vision and enhancing quality of life for patients globally.
What Are The Key Opportunities For Corneal Ulcer Treatment Manufacturers?
Manufacturers in the global corneal ulcer treatment are primarily focussing on enhancing their regional product offering because they want to cater a larger patient audience. Medical researchers are constantly developing new and innovative strategies to tune treatments for corneal ulcer treatment.
Various novel treatment options are for bacterial keratitis, fungal keratitis is undergoing clinical trials. Increasing the number of R&D activities for developing new drugs for treatment is one of the important factors which is expected to grow in market in the forecasted years.
Awareness of proper usage of contact lenses is also an important factor because it is closely linked to corneal ulcer. Especially in countries like India, where majority of our population is into agricultural activities are likely to be prone to corneal ulcers. These following opportunities could fuel the demand for manufacturers to expand their units and increase the production of the treatment options in order to serve the growing patient audience.
Competitive Landscape
Leading corneal ulcer treatment manufacturers are focusing on geographical expansion to gain high revenue & expand their sales footprint in emerging countries by acquisition of local market players.
Strategic collaborations, acquisitions, expansion, product launches, agreements and research sponsorship are the key strategies adopted by manufacturers to increase the product sales in different geographies.
- In December, 2019 Mallinckrodt plc enrolled its first in company’s Phase 4 multi centre, multiple- dose, open-label study to assess the effects of Achtar Gel as a therapy for patients with severe keratitis.
- In 2019, Dr Reddy’s Laboratory had filed 20 new Abbreviated New Drug Applications with USFDA.
Similarly, recent developments related to companies manufacturing corneal ulcer treatment products have been tracked by the team at Future Market Insights, which are available in the full report.
Key Companies Profiled
Pfizer Inc.; Allergen plc; Bayer AG; Teva Pharmaceutical Industries Ltd; Mallinckrodt Pharmaceuticals; Dr Reddy’s Pharmaceuticals; Sun Pharmaceutical Industries Ltd.; Baxter International Inc.; Fresenius Kabi
Get Complete Full Report
Key Market Segments Covered In Corneal Ulcer Treatment Industry Research
By Drug class:
- Antibiotics
- Antifungals
- Antivirals
- Corticosteroids
- NSAID’s
By Form:
- Tablet
- Eye Drops/ Ointments
- Vials
By Route of Administration:
- Oral
- Topical
- Injectables
By Indication:
- Bacterial Keratitis
- Fungal Keratitis
- Viral Keratitis
Acanthamoeba Keratitis:
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
- By Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube